Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Pfizer, Merck Biopharma to End Xalkori Copromotion in Japan
October 8, 2020
- Fujifilm to Expand Viral Vector CDMO Biz to Europe
October 8, 2020
- Hisamitsu Initiates Japan PIII of Palmar Hyperhidrosis Drug, Aims at Filing in FY2022
October 8, 2020
- 1 More Soft Bag Product Recalled Over Flawed Testing at Kyowa CritiCare
October 8, 2020
- HUYA Files Novel T-Cell Leukemia-Lymphoma Med in Japan
October 8, 2020
- Pfizer Renames Japan Subsidiaries as Mylan Deal Set to Close Soon; Upjohn Biz Now Separate
October 7, 2020
- Keytruda Top Selling Drug in September: Encise
October 7, 2020
- Eisai, 4 Research Organizations Begin Collaborative Project for COVID-19 Treatments
October 7, 2020
- Sunovion’s Apomorphine Sublingual Hits US Market
October 7, 2020
- Chugai Licenses Antibody Engineering Tech to argenx
October 7, 2020
- Armed with Enerzair, Novartis Looks to Establish Leading Position in Respiratory Arena
October 6, 2020
- Crysvita Approved in Europe for Adult XLH: Kyowa Kirin
October 6, 2020
- Nihon Chouzai’s Standard Formulary Service Fully Up and Running
October 5, 2020
- Axcelead, Kyowa Kirin Join Forces to Develop Small-Molecule Drugs
October 5, 2020
- Lilly’s Baqsimi Hits Japan Market, 1st Glucagon Nasal Powder
October 5, 2020
- AstraZeneca’s COVID-19 Vaccine Trial Resumes in Japan
October 5, 2020
- Chugai Seeks Label Expansion for FoundationOne as CDx for Pemigatinib, Larotrectinib
October 5, 2020
- Kyowa Kirin Commences Japan PII of Zandelisib for Indolent B-Cell Non-Hodgkin’s Lymphoma
October 5, 2020
- Novartis’ Tabrecta Hits Snag in Japan on Hospitals’ CDx Reimbursement Issue
October 2, 2020
- Maruishi to Discontinue Precedex after Pfizer Pact Expires
October 2, 2020
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…